Press releases

Gene Therapy Improves Heart Function in Hypertrophic Cardiomyopathy

Scientists at the University Hospital Hamburg-Eppendorf have shown that the sustained activation of tubulin tyrosination could be a novel treatment option for hypertrophic cardiomyopathy (HCM), a genetic heart condition causing heart muscle thickening and impaired diastolic function. HCM is the most common genetic cardiomyopathy and a leading cause of sudden cardiac death in young people.

 Induced pluripotent stem cell cardiomyocytes, stained for the sarcomeric protein ACTN2 (purple), detyrosinated microtubules (cyan) and DNA (orange), imaged with confocal microscopy at 63x magnification.
Monolayer human induced pluripotent stem cell cardiomyocytes stained for sarcomeric ACTN2 (purple), detyrosinated microtubules (cyan) and DNA (orange), imaged with confocal microscopy at 63x magnification.
 First author of the study Dr Niels Pietsch from the Institute of Experimental Pharmacology and Toxicology at the University Hospital Hamburg-Eppendorf.
First author of the study Dr Niels Pietsch from the Institute of Experimental Pharmacology and Toxicology at the University Hospital Hamburg-Eppendorf. Photos: UKE

The enzyme tubulin tyrosine ligase (TTL) plays a crucial role in regulating the stability of microtubules - part of the cell's cytoskeleton - which are responsible for cells' structural integrity and mechanical stability. TTL adds a tyrosine amino acid to tubulin proteins (tyrosination), affecting the flexibility of the microtubules and how cells respond to mechanical stress. This is especially important in heart muscle cells, where it supports contraction and the heart’s adaptation to pressure.

Reduced Myocardial Stiffness After 12 Weeks

In a series of experiments, the research team demonstrated that overexpression of TTL significantly improved heart function. In mouse models, after twelve weeks, the heart muscle cells showed reduced stiffness and improved contractility. 

Human heart muscle cells derived from stem cells of HCM patients also showed normalized cell size. These positive effects suggest a potential future therapy that could improve heart function without invasive procedures.

Hope for New Treatment Options

For approximately 160,000 persons affected by HCM in Germany, these findings offer hope for a new treatment option. This method could complement conventional medications or surgeries, improving patients' quality of life by stabilizing heart function and slowing disease progression. This could be especially important for those with severe symptoms, such as reduced heart performance or heart failure.

“Our results indicate that modulating the cytoskeleton through tubulin tyrosination offers a promising therapeutic strategy to improve heart function in genetic heart diseases like HCM.” says Prof. Dr. Lucie Carrier, the project’s lead scientist, Insitute of Experimental Pharmacology and Toxicology at the University Hospital Hamburg-Eppendorf.


Original publication:
Chronic Activation of Tubulin Tyrosination Improves Heart Function. Pietsch, N. et al., Circulation Research, 2024

Scientific contact
Prof. Dr Lucie Carrier (l.carrier@uke.de), Department of Experimental Pharmacology and Toxicology, Cardiovascular Research Center, UKE